AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03360266 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sodium fluoride with ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion
Study NCT03360266 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride with ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion
Study NCT03360266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride Varnish
Description: ffor children with ECC, this varnish effectively remineralizes the white spot lesion
Study NCT01388517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study NCT01388517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study NCT01388517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study NCT02738008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: IV injection
Study NCT02738008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT02738008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT02738008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study NCT00420576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBT-Danggui Buxue Tang
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
Study NCT05413746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reoxcare antioxidant dressing
Description: After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
Study NCT02028481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative air tamponade
Description: Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
Study NCT03550378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
Study NCT03550378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
Study NCT02988778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonid 50mcg (Noex)
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study NCT02988778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonid 50mcg (Busonid)
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study NCT01092728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: 100 mg daily.
Study NCT01092728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Complete surgical resection of tumor(s).
Study NCT04283305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality approach avoidance training
Description: In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
Study NCT04283305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based approach avoidance training
Description: In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
Study NCT02526277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MMF07 Foot Massager
Study NCT02526277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy
Study NCT03477734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS1 & heart monitor
Description: Daily activities while wearing the investigational device as well as the control device
Study NCT03477734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CS1 & heart monitor
Description: Daily activities while wearing the investigational device as well as the control device
Study NCT03790566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5 ml/kg 0.25% bupivacaine
Study NCT03790566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg 0.25% bupivacaine
Study NCT03502837 — intervention group
Intervention type: OTHER
Intervention: emotional sound and neutral sound
Description: Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli.
Study NCT00830544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
Study NCT00830544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Neoadjuvant chemotherapy
Study NCT00830544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Experimental chemotherapy regimen
Study NCT02670486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiovisual stimulus
Description: Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
Study NCT02107066 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
Study NCT02107066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
Study NCT02222571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Tots Together Program
Description: Group-based parenting program, 9 weeks delivered in a community setting
Study NCT02222571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervision for Safety
Description: group-based safety intervention for parents
Study NCT02166892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specially designed plates
Study NCT01140841 — intervention group
Intervention type: DRUG
Intervention: Fipamezole ODT
Description: Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
Study NCT01140841 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: 1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
Study NCT02812836 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manometry
Description: Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
Study NCT02319941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT02319941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Study NCT02319941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Study NCT03226717 — intervention group
Intervention type: DRUG
Intervention: Antiviral agents
Description: combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
Study NCT06187259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caries removal by carbide bur
Description: caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
Study NCT06187259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: caries removal by polymer bur II
Description: carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
Study NCT02972060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
Study NCT02972060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.
Study NCT01627977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dye of Lutein, Zeaxanthin and Brilliant Blue
Description: dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
Study NCT01918124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
Study NCT01918124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
Study NCT01918124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Doxorubicin and Cyclophosphamide
Description: Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
Study NCT01918124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
Study NCT04247386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Mizone
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water.
Study NCT04247386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
Study NCT03062735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
Study NCT03062735 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Muscle Training
Description: The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
Study NCT02758717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT02758717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03767647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence lessons
Description: 6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
Study NCT02734693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 4mg
Description: dasotraline 4mg/day
Study NCT02734693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo/day
Study NCT02050477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Vertical Gastroplasty
Description: The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
Study NCT02647307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: Single 12-hour intravenous infusion of DS-1040b (20 mg)
Study NCT01480661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 500 µg, once a day in the morning during 6 months
Study NCT01480661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Roflumilast
Description: Placebo 500 µg, once a day in the morning during 6 months
Study NCT01480661 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT scan of thorax, at baseline and after 6 months
Study NCT01480661 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT scan of thorax, at baseline and after 6 months
Study NCT03918616 — intervention group
Intervention type: DRUG
Intervention: Memantine, Dopamine receptor-agonists
Description: The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
Study NCT00837902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol (β-blocker)
Description: 25 mg tablet
Study NCT01869738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard Prime
Study NCT01869738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (BMS/DES)
Study NCT01832077 — intervention group
Intervention type: DEVICE
Intervention: 90 D
Description: rural doctors exam eye fundus by 90 D
Study NCT01832077 — intervention group
Intervention type: DEVICE
Intervention: fundus camera and grader
Description: taking fundus pictures and graded by graders in ZOC
Study NCT02005016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naming therapy
Description: Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
Study NCT04622111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Study NCT04622111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study NCT04622111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 750 mg
Description: IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
Study NCT02151487 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Description: Ropivacaine alone
Study NCT02151487 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine and dexamethasone
Description: Ropivacaine combination with dexamethasone
Study NCT02151487 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine and clonidine
Description: Ropivacaine combination with clonidine
Study NCT02151487 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine, dexamethasone and clonidine
Description: Ropivacaine combination with dexamethasone and clonidine
Study NCT03139760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERSforID
Description: Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
Study NCT00694616 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AutoSet Spirit
Description: 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
Study NCT00694616 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Modified-AutoSet Spirit
Description: 3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
Study NCT02949609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
Study NCT02949609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
Study NCT03798106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, pazopanib
Description: Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
Study NCT00549692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethylester90
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.
Study NCT00549692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acid ethylester90
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.
Study NCT04363203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.
Study NCT04363203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
Study NCT04363203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo in pill packs identical to study drugs
Study NCT01636765 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: No intervention.
Study NCT01361555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-820836
Description: Tablet, Oral, 0.0 mg, Once daily, 54 weeks
Study NCT01361555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.5 mg, Once daily, 54 weeks
Study NCT01361555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 1.0 mg, Once daily, 54 weeks